<DOC>
	<DOCNO>NCT00299650</DOCNO>
	<brief_summary>The use neuromuscular blocking agent ( NMBA ) ARDS patient extensively investigate . The aim study show reduction mortality rate ARDS patient .</brief_summary>
	<brief_title>Systematic Early Use Neuromuscular Blocking Agents ARDS Patients</brief_title>
	<detailed_description>The use neuromuscular blocking agent ( NMBA ) ARDS patient extensively investigate . It recently demonstrate systematic 48-h infusion NMBA associate significant improvement oxygenation compare control group ( Gainnier et al. , Crit Care Med 2004 ) . Moreover , trend towards reduction mortality rate observe . The aim study show reduction mortality rate ARDS patient .</detailed_description>
	<mesh_term>Neuromuscular Blocking Agents</mesh_term>
	<mesh_term>Cisatracurium</mesh_term>
	<mesh_term>Atracurium</mesh_term>
	<criteria>ARDS PaO2 / FiO2 &lt; 150 PEEP &gt; 5 since less 48 hr inform consent NMBA allergy Continuous administration NMBA ARDS prior inclusion Age &lt; 18 yr SAPS II &gt; 70 Persistent air leak</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>ARDS</keyword>
	<keyword>mortality</keyword>
	<keyword>mechanical ventilation</keyword>
	<keyword>pneumonia</keyword>
	<keyword>muscle relaxant</keyword>
</DOC>